Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:4362 |
Name | cervical cancer |
Definition | A female reproductive organ cancer that is located_in the cervix. |
Source | DiseaseOntology.org |
Alt Ids | DOID:4361 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer cervical cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA E545K | PW12 | cervical cancer | sensitive | detail... |
PIK3CA mutant | Cetuximab | cervical cancer | decreased response | detail... |
Unknown unknown | Mps-BAY2b + Paclitaxel | cervical cancer | not applicable | detail... |
Unknown unknown | BIND-014 | cervical cancer | not applicable | detail... |
Unknown unknown | Pimitespib + Radiotherapy | cervical cancer | not applicable | detail... |
Unknown unknown | Tozasertib | cervical cancer | not applicable | detail... |
Unknown unknown | BIRB-796 + Tozasertib | cervical cancer | not applicable | detail... |
Unknown unknown | ETP-46464 + Radiotherapy | cervical cancer | not applicable | detail... |
Unknown unknown | Cisplatin + ETP-46464 | cervical cancer | not applicable | detail... |
Unknown unknown | Cisplatin + VE-821 | cervical cancer | not applicable | detail... |
AKT1 E17K | Capivasertib | cervical cancer | predicted - sensitive | detail... |
Unknown unknown | BMS-986205 + Nivolumab | cervical cancer | not applicable | detail... |
ERBB2 mutant | Neratinib | cervical cancer | predicted - sensitive | detail... |
ERBB2 D769N | Neratinib | cervical cancer | no benefit | detail... |
ERBB2 S310F | Neratinib | cervical cancer | predicted - sensitive | detail... |
ERBB2 S310Y | Neratinib | cervical cancer | predicted - resistant | detail... |
PIK3CA mutant | Alpelisib | cervical cancer | predicted - sensitive | detail... |
Unknown unknown | Tisotumab Vedotin | cervical cancer | not applicable | detail... |
Unknown unknown | AsiDNA | cervical cancer | not applicable | detail... |
Unknown unknown | AsiDNA + Olaparib | cervical cancer | not applicable | detail... |
Unknown unknown | PRGN-2009 | cervical cancer | not applicable | detail... |
PIK3CA mutant | Perifosine | cervical cancer | not predictive | detail... |
ERBB2 act mut | Neratinib | cervical cancer | predicted - sensitive | detail... |
ERBB2 S310F ERBB2 V842I | Neratinib | cervical cancer | predicted - sensitive | detail... |
ERBB2 R678Q | Neratinib | cervical cancer | predicted - sensitive | detail... |
ERBB2 G776V | Neratinib | cervical cancer | predicted - sensitive | detail... |
Unknown unknown | TG6002 | cervical cancer | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00292955 | Phase II | Cetuximab Cisplatin | Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma | Unknown status | USA | 0 |
NCT00980954 | Phase III | Carboplatin + Paclitaxel Cisplatin | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | Recruiting | USA | CAN | 2 |
NCT01711515 | Phase I | Ipilimumab Cisplatin | Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer | Completed | USA | 0 |
NCT01958112 | Phase II | Trametinib + Uprosertib | GSK1120212+GSK2141795 for Cervical Cancer | Terminated | USA | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | 2 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Recruiting | USA | CAN | 13 |
NCT02100007 | Phase Ib/II | ME-344 + Topotecan | ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors | Terminated | USA | 1 |
NCT02312804 | Phase I | Paclitaxel Carboplatin Infigratinib | Ph Ib/BGJ398/Cervix and Other Solid Tumors | Withdrawn | 0 | |
NCT02405221 | Phase I | TA-CIN | Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer | Recruiting | USA | 0 |
NCT02426892 | Phase II | Nivolumab | Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | Active, not recruiting | USA | 0 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT02479178 | Phase II | BIND-014 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) | Terminated | USA | 1 |
NCT02487095 | Phase Ib/II | Berzosertib Topotecan | Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02488759 | Phase Ib/II | Nivolumab | A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) | Active, not recruiting | USA | 10 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | 1 |
NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Recruiting | USA | 0 |
NCT02631733 | Phase I | Irinotecan + Veliparib | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Suspended | USA | 0 |
NCT02635360 | Phase II | Cisplatin Pembrolizumab | Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer | Recruiting | USA | 0 |
NCT02661815 | Phase I | Paclitaxel + Ricolinostat Bevacizumab | A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer | Terminated | USA | 0 |
NCT02671955 | Phase I | JNJ-61610588 | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02725489 | Phase II | Durvalumab + FANG vaccine | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | Completed | USA | 0 |
NCT02812056 | Phase I | Alisertib + Sapanisertib | Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies | Withdrawn | 0 | |
NCT02865135 | Phase Ib/II | Cyclophosphamide + DPX-E7 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | Active, not recruiting | USA | 0 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Recruiting | USA | 0 |
NCT03023319 | Phase I | Bosutinib + Pemetrexed Disodium | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03104699 | Phase Ib/II | Balstilimab | Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer | Active, not recruiting | USA | 8 |
NCT03188965 | Phase I | BAY1895344 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | CAN | 7 |
NCT03257267 | Phase III | Irinotecan Gemcitabine Vinorelbine Pemetrexed Disodium Cemiplimab Topotecan | Study of REGN2810 in Adults With Cervical Cancer | Active, not recruiting | USA | CAN | 12 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Recruiting | USA | 0 |
NCT03427411 | Phase II | M7824 | Phase II Trial of M7824 in Subjects With HPV Positive Malignancies | Recruiting | USA | 0 |
NCT03439085 | Phase II | Durvalumab + MEDI0457 | Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers | Recruiting | USA | 0 |
NCT03452332 | Phase I | Durvalumab + Tremelimumab | Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Cervical, Vaginal, or Vulvar Cancer | Recruiting | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Recruiting | USA | 1 |
NCT03508570 | Phase I | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | Recruiting | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Recruiting | USA | 0 |
NCT03527264 | Phase II | Cisplatin + Nivolumab | BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer | Recruiting | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Active, not recruiting | USA | CAN | 1 |
NCT03614949 | Phase II | Atezolizumab | SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer | Recruiting | USA | 0 |
NCT03618953 | Phase I | Ad-E6E7 + Atezolizumab + MG1-E6E7 | This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers (Kingfisher) | Active, not recruiting | USA | CAN | 0 |
NCT03666273 | Phase I | BAY1905254 BAY1905254 + Pembrolizumab | A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 | Recruiting | USA | 0 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Recruiting | USA | 5 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | 0 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Recruiting | USA | 3 |
NCT03917381 | Phase Ib/II | GEN1046 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Recruiting | USA | 2 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Active, not recruiting | USA | 4 |
NCT03968406 | Phase I | Talazoparib | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | Recruiting | USA | 0 |
NCT04068753 | Phase II | Dostarlimab + Niraparib | Niraparib in Combination With TSR-042 in Patients With Recurrent or Progressive Cervix Cancer (STAR) | Recruiting | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04122625 | Phase Ib/II | Debio 1143 + Nivolumab | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Recruiting | USA | 2 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Recruiting | USA | 2 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04287868 | Phase Ib/II | M7824 + NHS-IL12 + PDS0101 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Recruiting | USA | 0 |
NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | 3 |
NCT04395079 | Phase II | Tremelimumab Durvalumab | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | Recruiting | USA | 0 |
NCT04423029 | Phase Ib/II | DF6002 + Pembrolizumab DF6002 | Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications | Recruiting | USA | 0 |
NCT04432597 | Phase Ib/II | PRGN-2009 M7824 + PRGN-2009 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | Recruiting | USA | 0 |
NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Recruiting | USA | CAN | 11 |
NCT04493619 | Phase Ib/II | Carboplatin + PLX2853 PLX2853 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | Recruiting | USA | CAN | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Recruiting | USA | CAN | 2 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04708470 | Phase Ib/II | Entinostat + M7824 + NHS-IL12 | Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer | Not yet recruiting | USA | 0 |